In 2025, Laboratorios Farmaceuticos ROVI completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Laboratorios Farmaceuticos ROVI has also provided a category-level breakdown for 6 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 9,011.86a | 9,525.38a | 8,240.43b | |
Total Scope 2 | ||||
Market-Based | 36.79a | 38.6a | 50.84b | |
Location-Based | 9,733.69a | 9,225.13a | 8,389.16b | |
Unspecified Calculation Method | N/A | N/A | N/A | |
Total Scope 3 | 55,106.99a | 57,127.31a | 10,347.43b | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 10.3101a | 11.9851a | 8.9754b |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Laboratorios Farmaceuticos ROVI amounted to 18,745.55 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Laboratorios Farmaceuticos ROVI decreased by 0.03%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2025, the total Scope 1 emissions of Laboratorios Farmaceuticos ROVI were 9,011.86 metric tons of CO₂ equivalent (tCO₂e).a
Since 2021, Laboratorios Farmaceuticos ROVI's Scope 1 emissions have increased by 44.65%, reflecting a rising long-term trend in Scope 1 emissions over time.ac
Compared to the previous year (2024), Laboratorios Farmaceuticos ROVI's Scope 1 emissions decreased by 5.39%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2025, Laboratorios Farmaceuticos ROVI reported Scope 2 greenhouse gas (GHG) emissions of 36.79 tCO₂e using the market-based method and 9,733.69 tCO₂e using the location-based method.a
Compared to the previous year (2024), Laboratorios Farmaceuticos ROVI's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Laboratorios Farmaceuticos ROVI's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2025, Laboratorios Farmaceuticos ROVI reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2025, Laboratorios Farmaceuticos ROVI reported 55,106.99 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Laboratorios Farmaceuticos ROVI includes a breakdown across 6 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, Laboratorios Farmaceuticos ROVI reported total Scope 3 emissions of 55,106.99 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2024), Laboratorios Farmaceuticos ROVI's Scope 3 emissions remained relatively stable, indicating that Laboratorios Farmaceuticos ROVI's emissions have plateaued with no significant change in its value chain footprint.a
In 2025, Laboratorios Farmaceuticos ROVI reported emissions for 6 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
In 2025, the largest contributors to Laboratorios Farmaceuticos ROVI's Scope 3 emissions were:a
In 2025, Laboratorios Farmaceuticos ROVI reported Scope 1 greenhouse gas (GHG) emissions of 9,011.86 tCO₂e and total revenues of USD 874 millions. This translates into an emissions intensity of 10.31 tCO₂e per millions USD.a
In 2025, Laboratorios Farmaceuticos ROVI reported a Scope 1 emissions intensity of 10.31 tCO₂e per millions USD. Compared to the peer group median of 12.64, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, Laboratorios Farmaceuticos ROVI ranked 11 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Laboratorios Farmaceuticos ROVI is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2025, Laboratorios Farmaceuticos ROVI reported a total carbon footprint of 73,852.54 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 2.67% decrease compared to 2024, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Laboratorios Farmaceuticos ROVI's total carbon footprint was Scope 3 emissions, accounting for 74.62% of the company's total carbon footprint, followed by Scope 2 emissions at 13.18%.a